BioStock: CAR T deal puts spotlight on Elicera’s technology

Is the hype around CAR T-cell therapies real? A recent licensing agreement struck between Legend Biotech and Novartis to advance novel CAR T candidates suggests it might be. The deal raises commercial hopes for other players in the CAR T space, including Swedish biotech Elicera Therapeutics. We asked Elicera’s CEO Jamal El-Mosleh whether Elicera could be bound for a similar deal.

Read the interview with Jamal El-Mosleh at biostock.se:

CAR T deal puts spotlight on Elicera’s technology - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/